Company Description
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout.
Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
| Country | United States |
| Founded | 2018 |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Yu-Hsin Lin |
Contact Details
Address: 12750 High Bluff Drive, Suite 475 San Diego, California 92130 United States | |
| Phone | 858 246 6240 |
| Website | belitebio.com |
Stock Details
| Ticker Symbol | BLTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 1889109 |
| CUSIP Number | 07782B104 |
| ISIN Number | US07782B1044 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors and Chief Executive Officer |
| Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | Chief Financial Officer and Director |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2025 | SCHEDULE 13G | Filing |
| Dec 2, 2025 | 424B5 | Filing |
| Dec 2, 2025 | 6-K | Report of foreign issuer |
| Dec 1, 2025 | 424B5 | Filing |
| Dec 1, 2025 | 6-K | Report of foreign issuer |
| Dec 1, 2025 | 6-K | Report of foreign issuer |
| Dec 1, 2025 | 6-K | Report of foreign issuer |
| Nov 10, 2025 | 6-K | Report of foreign issuer |
| Oct 22, 2025 | F-3ASR | Filing |
| Oct 17, 2025 | 144 | Filing |